rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ZVRA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Guggenheim cuts Zevra Therapeutics price target on EU setback
      Nov 16Investing.comZVRA
      Zevra’s Lead Drug Faces Potential European Setback – ZVRA Stock Heads For Worst Day In A Month
      Nov 13Yahoo FinanceZVRA
      Zevra gets negative EU opinion for rare disease drug
      Nov 13Investing.comZVRA
      Zevra Therapeutics Announces Final CHMP Opinion on Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
      Nov 13Yahoo FinanceZVRA
      Wall Street Analysts Believe Zevra Therapeutics (ZVRA) Could Rally 117.86%: Here's is How to Trade
      Nov 9Yahoo FinanceZVRA
      Zevra Therapeutics, Inc. Q3 2026 Earnings Call Summary
      Nov 4Yahoo FinanceZVRA
      Zevra Therapeutics Inc (ZVRA) (Q3 2026) Earnings Call Highlights: Revenue Jumps 45% as MIPLYFFA ...

      Zevra Therapeutics Inc (ZVRA) posted $37.8 million in Q3 2026 revenue, swung to $19.2 million net income, and outlined plans for an infant label expansion and a Q4 European decision on arimoclomol.

      Nov 4Yahoo FinanceZVRA
      Zevra Therapeutics Q3 Earnings Call Highlights
      Nov 3Yahoo FinanceZVRA
      Zevra Therapeutics Q3 2026 Earnings Call Transcript
      Nov 3BenzingaZVRA
      Earnings call transcript: Zevra tops Q3 2026 estimates as MIPLYFFA sales surge
      Nov 3Investing.comZVRA
      Zevra Therapeutics earnings beat by $0.10, revenue topped estimates
      Nov 3Investing.comZVRA
      Zevra Therapeutics (ZVRA) Q3 Earnings and Revenues Beat Estimates
      Nov 3Yahoo FinanceZVRA
      Zevra Therapeutics: Q3 Earnings Snapshot
      Nov 3Yahoo FinanceZVRA
      Zevra Reports Third Quarter 2026 Financial Results and Corporate Update

      $37.8 million net revenue for Q3 2026, driven by $34.0 million in revenue from MIPLYFFA 45% increase in total net revenue over Q3 2025 Operational execution fueled strong cash position of $270.9 million Company to host conference call and webcast TODAY, November 3, 2026, at 4:30 p.m. ET BOSTON, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with

      Nov 3Yahoo FinanceZVRA
      Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call
      Oct 20Yahoo FinanceZVRA
      Zevra Therapeutics: Cash Plus A Drug Priced Below Its Rival's Deal (NASDAQ:ZVRA)
      Oct 15Seeking AlphaZVRA
      Zevra Therapeutics president and CEO sells $224,948 in stock
      Oct 14Investing.comZVRA
      Zevra Therapeutics: Miplyffa Validates The Bull Case, Europe Still The Swing Factor (ZVRA)

      Zevra Therapeutics is a buy-rated, single-asset rare disease play with Miplyffa driving strong U.S. growth and early profitability. Learn more about ZVRA stock here.

      Oct 6Seeking AlphaZVRA
      Zevra Therapeutics at H.C. Wainwright: rare-disease growth broadens
      Sep 15Investing.comZVRA
      Zevra at Morgan Stanley conference: rare-disease market looks bigger
      Sep 14Investing.comZVRAMS
      Zevra Therapeutics at Cantor conference: growth, cash and rare-disease bets
      Sep 9Investing.comZVRA
      Zevra Therapeutics to Present at Upcoming Investor Conferences
      Sep 2Yahoo FinanceZVRA
      Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium

      Presentations from U.S. and German early access programs highlight sustained disease stabilization and a consistent safety profile across diverse NPC patient populations

      Aug 25BarchartZVRA

      This is the newest page. Registered accounts read further back.